Tuberkulosis (TB) hingga saat ini menjadi salah satu masalah kesehatan masyarakat dunia. Di Indonesia, prevalensi infeksi TB mencapai 8,5% dan merupakan angka prevalensi TB terbesar kedua di dunia pada tahun 2019. Dalam rangka mendukung keberhasilan program penanggulangan TB nasional, dilaksanakan upaya pemantauan dan evaluasi keberhasilan program penanggulangan TB di Indonesia. Sejak bulan Maret 2022 – Mei 2023, puskesmas kecamatan cengkareng telah melayani 166 pasien dewasa TB Sensitif Obat (TB-SO) dosis intermiten. Dalam rangka menilai keberhasilan program tersebut, dilakukan evaluasi hasil pengobatan periode Maret 2022 – April 2023 serta dilakukan penyusun leaflet sebagai sarana edukasi pengobatan TB-SO dosis intermiten. Evaluasi pengobatan dilaksanakan melalui pengelolahan data retrospektif menggunakan perangkat lunak Microsoft excel dari data sekunder hasil rekapitulasi pengobatan OAT 2HRZE/4H3R3 sejak bulan Maret 2022 – Mei 2023. Sedangkan, pembuatan leaflet dilakukan berdasarkan studi literatur dari pustaka tahun 2009 – 2021 dan ditulis secara ringkas dan menarik. Berdasarkan hasil evaluasi, dari 166 pasien dewasa TB-SO dosis intermiten; 48,80% pasien sembuh; 13,25% pasien dirujuk ke fasilitas kesehatan lain; 9,64% pasien Loss to Follow Up; 0,6% pasien meninggal; 21,08% pasien menjalankan terapi fase awal; dan 6,63% pasien menjalankan terapi fase lanjutan. Selain itu, telah dibuat leaflet pengobatan TB dosis 4HRZE/2H3R3 sebagai media edukasi bagi pasien TB.

---

Tuberculosis (TB) has become one of the world's public health problems. In Indonesia, the prevalence of TB infection reached 8.5% and was the second highest TB prevalence in the world in 2019. To support the success of the national TB program, evaluation, and monitoring of TB programs in Indonesia were carried out. From March 2022 – May 2023, Puskesmas kecamatan cengkareng has treated 166 adult patients with drug-sensitive TB (SO-TB). To assess the success of the program, an evaluation of the treatment was carried out and the leaflet was compiled as an educational media. The evaluation was carried out retrospectively using secondary data from the recapitulation of OAT 2HRZE/4H3R3 treatment from March 2022 – May 2023, all the data were processed using Microsoft Excel software. Meanwhile, the leaflet was created based on literature studies from the 2009 – 2021 literature. Based on the evaluation results, from 166 adult patients with intermittent dose TB-SO; 48.80% of the patients recovered; 13.25% of patients were referred to other health facilities; 9.64% of patients were Loss to Follow Up; 0.6% of patients died; 21.08% of patients underwent intensive phase therapy; and 6.63% of patients underwent continuous phase therapy. In addition, the leaflet for drug-sensitive TB has been made as educational media for TB patients.